These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22180752)

  • 41. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanism of Tetherin Inhibition of Alphavirus Release.
    Wan JJ; Ooi YS; Kielian M
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.
    Yan R; Zhao X; Cai D; Liu Y; Block TM; Guo JT; Guo H
    J Virol; 2015 Sep; 89(18):9200-12. PubMed ID: 26109732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiviral Activity and Adaptive Evolution of Avian Tetherins.
    Krchlíková V; Fábryová H; Hron T; Young JM; Koslová A; Hejnar J; Strebel K; Elleder D
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32238588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel peptide to disrupt the interaction of BST-2 and Vpu.
    Mi Z; Wang X; He Y; Li X; Ding J; Liu H; Zhou J; Cen S
    Biopolymers; 2014 May; 102(3):280-7. PubMed ID: 24676648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Counteraction of the multifunctional restriction factor tetherin.
    Sauter D
    Front Microbiol; 2014; 5():163. PubMed ID: 24782851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.
    Shingai M; Yoshida T; Martin MA; Strebel K
    J Virol; 2011 Oct; 85(19):9708-15. PubMed ID: 21775449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain.
    Hinz A; Miguet N; Natrajan G; Usami Y; Yamanaka H; Renesto P; Hartlieb B; McCarthy AA; Simorre JP; Göttlinger H; Weissenhorn W
    Cell Host Microbe; 2010 Apr; 7(4):314-323. PubMed ID: 20399176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tetherin Antagonism by HIV-1 Group M Nef Proteins.
    Arias JF; Colomer-Lluch M; von Bredow B; Greene JM; MacDonald J; O'Connor DH; Serra-Moreno R; Evans DT
    J Virol; 2016 Dec; 90(23):10701-10714. PubMed ID: 27654287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bending of the BST-2 coiled-coil during viral budding.
    Ozcan KA; Berndsen CE
    Proteins; 2017 Nov; 85(11):2081-2087. PubMed ID: 28779494
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse.
    Blanchet FP; Stalder R; Czubala M; Lehmann M; Rio L; Mangeat B; Piguet V
    Retrovirology; 2013 Jan; 10():6. PubMed ID: 23311681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release.
    Andrew AJ; Berndsen CE; Kao S; Strebel K
    J Biol Chem; 2012 Dec; 287(53):44278-88. PubMed ID: 23152502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of the interface of the bone marrow stromal cell antigen 2-Vpu protein complex via computational chemistry.
    Zhou J; Zhang Z; Mi Z; Wang X; Zhang Q; Li X; Liang C; Cen S
    Biochemistry; 2012 Feb; 51(6):1288-96. PubMed ID: 22264038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
    Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
    Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Positioning of cysteine residues within the N-terminal portion of the BST-2/tetherin ectodomain is important for functional dimerization of BST-2.
    Welbourn S; Kao S; Du Pont KE; Andrew AJ; Berndsen CE; Strebel K
    J Biol Chem; 2015 Feb; 290(6):3740-51. PubMed ID: 25525265
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The great escape: viral strategies to counter BST-2/tetherin.
    Douglas JL; Gustin JK; Viswanathan K; Mansouri M; Moses AV; Früh K
    PLoS Pathog; 2010 May; 6(5):e1000913. PubMed ID: 20485522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epitope tags beside the N-terminal cytoplasmic tail of human BST-2 alter its intracellular trafficking and HIV-1 restriction.
    Lv M; Wang J; Zhang J; Zhang B; Wang X; Zhu Y; Zuo T; Liu D; Li X; Wu J; Zhang H; Yu B; Wu H; Zhao X; Kong W; Yu X
    PLoS One; 2014; 9(10):e111422. PubMed ID: 25347789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release.
    Swiecki M; Scheaffer SM; Allaire M; Fremont DH; Colonna M; Brett TJ
    J Biol Chem; 2011 Jan; 286(4):2987-97. PubMed ID: 21084286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The interferon-inducible host factor bone marrow stromal antigen 2/tetherin restricts virion release, but is it actually a viral restriction factor?
    Andrew A; Strebel K
    J Interferon Cytokine Res; 2011 Jan; 31(1):137-44. PubMed ID: 21166593
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of BST-2/tetherin-induced hepatitis B virus restriction and hepatocyte-specific BST-2 inactivation.
    Lv M; Zhang B; Shi Y; Han Z; Zhang Y; Zhou Y; Zhang W; Niu J; Yu XF
    Sci Rep; 2015 Jun; 5():11736. PubMed ID: 26119070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.